Tevogen Bio Holdings(TVGN),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

TVGN Tevogen Bio Holdings

Pre-Mkt 04-22 06:08:52 EDT

8.65

+0.35

+4.22%

High9.40	Low7.65	Vol71.53K
Open9.30	D1 Closing8.30	Amplitude21.14%
Mkt Cap36.02M	Tradable Cap9.80M	Total Shares4.16M
T/O633.26K	T/O Rate6.31%	Tradable Shares1.13M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"TVGN","market":"US","secType":"STK","nameCN":"Tevogen Bio Holdings","latestPrice":8.65,"timestamp":1776801600000,"preClose":8.3,"halted":0,"volume":71527,"delay":0,"changeRate":0.042168674698795136,"floatShares":1133000,"shares":4164205,"eps":-8.080406,"marketStatus":"Pre-Mkt","change":0.35,"latestTime":"04-22 06:08:52 EDT","open":9.3,"high":9.4,"low":7.645,"amount":633255.1390440001,"amplitude":0.211446,"askPrice":9.5,"askSize":55,"bidPrice":8.15,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-8.080406,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1776864600000},"marketStatusCode":1,"adr":0,"exchange":"NASDAQ","adjPreClose":8.65,"postHourTrading":{"tag":"盘后","latestPrice":8.65,"preClose":8.65,"latestTime":"19:24 EDT","volume":157,"amount":1297.2862,"timestamp":1776813859713,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":2.8679513190481307},"requestUrl":"/m/hq/s/TVGN","defaultTab":"news","newsList":[{"id":"2624152553","title":"Tevogen Bio FY25 net loss widens to $26.3 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2624152553","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624152553?lang=en_us&edition=fundamental","pubTime":"2026-04-01 05:17","pubTimestamp":1774991859,"startTime":"0","endTime":"0","summary":"Tevogen Bio posted a net loss of $26.3 million for fiscal 2025.Operating loss narrowed to $26.1 million from $53.6 million a year earlier.Research and development expense fell to $11.1 million, due mainly to lower non-cash stock-based compensation.Management said cash resources should fund operations for at least 12 months from issuance of the financial statements.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tevogen Bio Holdings Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 31, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260331:nNDL5nFlRB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TVGN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622898459","title":"BRIEF-Tevogen Advances Strategic CRO Evaluation To Expand Clinical Research Delivery Capabilities And Drive Revenue Growth","url":"https://stock-news.laohu8.com/highlight/detail?id=2622898459","media":"Reuters","labels":["corporation","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622898459?lang=en_us&edition=fundamental","pubTime":"2026-03-27 02:12","pubTimestamp":1774548761,"startTime":"0","endTime":"0","summary":"BRIEF-Tevogen Advances Strategic CRO Evaluation To Expand Clinical Research Delivery Capabilities And Drive Revenue GrowthMarch 26 (Reuters) - Tevogen Bio Holdings Inc TVGN.O:TEVOGEN ADVANCES STRATEGI","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260326:nFWN40E14J:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TVGN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622867698","title":"Tevogen Bio Holdings: Opportunity Expected to Contribute More Than $20 Mln in Annual Revenue While Supporting Double-Digit Growth Beginning Next Year","url":"https://stock-news.laohu8.com/highlight/detail?id=2622867698","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622867698?lang=en_us&edition=fundamental","pubTime":"2026-03-27 00:46","pubTimestamp":1774543580,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260326:nFWN40E14J:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["TVGN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622867669","title":"Tevogen Advances Strategic Cro Evaluation to Expand Clinical Research Delivery Capabilities and Drive Revenue Growth","url":"https://stock-news.laohu8.com/highlight/detail?id=2622867669","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622867669?lang=en_us&edition=fundamental","pubTime":"2026-03-27 00:46","pubTimestamp":1774543580,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260326:nFWN40E14J:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["TVGN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622007626","title":"Tevogen Bio implements 1-for-50 reverse stock split; Nasdaq bid-price compliance returns","url":"https://stock-news.laohu8.com/highlight/detail?id=2622007626","media":"Reuters","labels":["executive","shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622007626?lang=en_us&edition=fundamental","pubTime":"2026-03-26 05:05","pubTimestamp":1774472747,"startTime":"0","endTime":"0","summary":"Tevogen implemented a 1-for-50 reverse stock split that became effective on March 6, 2026.Nasdaq notified Tevogen on March 20, 2026 that it regained compliance with the minimum bid price requirement under Listing Rule 5450 following the reverse split.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tevogen Bio Holdings Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 25, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260325:nNDL2VtgJZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive,shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TVGN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622009461","title":"Tevogen Bio Regains Compliance With Nasdaq Listing Rule","url":"https://stock-news.laohu8.com/highlight/detail?id=2622009461","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622009461?lang=en_us&edition=fundamental","pubTime":"2026-03-26 02:55","pubTimestamp":1774464915,"startTime":"0","endTime":"0","summary":"Tevogen Bio (TVGN) said Wednesday it has regained compliance with Nasdaq's listing rule of maintaining a minimum bid price of $1 per share for 30 consecutive trading days.Shares of Tevogen Bio fell 1.3% on Wednesday.Price: 5.15, Change: -0.07, Percent Change: -1.34","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","TVGN","NQmain"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622009591","title":"Tevogen regains compliance with Nasdaq minimum bid price requirement","url":"https://stock-news.laohu8.com/highlight/detail?id=2622009591","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622009591?lang=en_us&edition=fundamental","pubTime":"2026-03-26 02:25","pubTimestamp":1774463130,"startTime":"0","endTime":"0","summary":"Tevogen (TVGN) received written notice from the Nasdaq notifying the company that it had regained compliance with the minimum bid price requirement...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/tevogen-regains-compliance-with-nasdaq-minimum-bid-price-requirement-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/tevogen-regains-compliance-with-nasdaq-minimum-bid-price-requirement-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NQmain","TVGN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622062340","title":"Tevogen Regains Compliance With Nasdaq Minimum Bid Price Requirement","url":"https://stock-news.laohu8.com/highlight/detail?id=2622062340","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622062340?lang=en_us&edition=fundamental","pubTime":"2026-03-26 02:20","pubTimestamp":1774462800,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260325:nTUA97R3MN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["TVGNW","TVGN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621084421","title":"Tevogen Bio Holdings Inc  expected to post a loss of $2.00 a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2621084421","media":"Reuters","labels":["preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621084421?lang=en_us&edition=fundamental","pubTime":"2026-03-24 04:34","pubTimestamp":1774298045,"startTime":"0","endTime":"0","summary":"Tevogen Bio Holdings Inc  expected to post a loss of $2.00 a share - Earnings Preview Tevogen Bio Holdings Inc TVGN.OQ TVGN.O is expected to  report resultson March 25 (estimated) for the period endin","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"ab6e84fb0542480d9cf75cb6a9fe5601","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260323:nL8N40B2DJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","TVGN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620268410","title":"Tevogen CIO Mittul Mehta to Speak at Microsoft Fabric Community Conference FabCon 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2620268410","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620268410?lang=en_us&edition=fundamental","pubTime":"2026-03-19 00:22","pubTimestamp":1773850950,"startTime":"0","endTime":"0","summary":"Tevogen said its CIO and head of Tevogen.AI, Mittul Mehta, will speak at the Microsoft Fabric Community Conference  in Atlanta, Georgia, on March 16-20, 2026. He is scheduled to join a session on March 18, 2026, from 4:30 PM to 5:05 PM. He is also scheduled to join a session on March 19, 2026, from 4:15 PM to 5:15 PM.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260318:nNDL5P85P5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2092627202.USD","LU0265550946.USD","IE00B19Z9505.USD","LU1670711040.USD","LU0256863811.USD","BK4612","LU0345769128.USD","LU2430703095.HKD","LU1066051225.USD","LU1935042991.SGD","LU2471134952.CNY","LU2077746001.SGD","LU0323591593.USD","LU0345774631.USD","LU0308772762.SGD","LU0642271901.SGD","LU1228905540.USD","IE0009G5SDU7.USD","LU2896262040.SGD","LU1003077747.HKD","LU1548497426.USD","BK4577","IE00BDCRKT87.USD","LU0985320562.USD","IE00BJJMRX11.SGD","LU1035775433.USD","LU2430703178.SGD","LU0289739343.SGD","IE00BLSP4452.SGD","LU0994945656.USD","LU0882574139.USD","IE00BN0W2V16.EUR","LU0124676726.USD","LU0965509283.SGD","IE00B19Z8X17.USD","IE00BJLML261.HKD","LU0094547139.USD","LU0719512351.SGD","LU1116320737.USD","LU2089283258.USD","LU0109391861.USD","LU1400636491.USD","LU0210536198.USD","LU2456880835.USD","LU1228905037.USD","LU1951198990.SGD","IE00B7KXQ091.USD","BK4534","BK4525","IE00BKPKM429.USD","LU2111349929.HKD","LU0708995401.HKD","LU2347655156.SGD","TVGN","LU1989772923.USD","IE00BKDWB100.SGD","LU0048584097.USD","LU2362541273.HKD","LU1642822529.SGD","LU1778281490.HKD","BK4585","LU0203202063.USD","IE0034235188.USD","LU1852331112.SGD","LU0964807845.USD","LU1400636574.HKD","LU1496350171.SGD","SG9999001077.SGD","LU2750360997.AUD","LU2433249047.HKD","LU2065171311.SGD","LU1823568750.SGD","IE00B4JS1V06.HKD","BK4528","LU2028103732.USD","LU2213496289.HKD","LU0323239441.USD","LU1803068623.USD","IE00BFXG0V08.USD","LU0096362180.USD","LU0072461881.USD","LU0894486033.HKD","LU1989763005.USD","SG9999014880.SGD","BK4566","IE000W1ABFV2.USD","LU2083900584.USD","LU0426412945.USD","LU0957808578.USD","LU2458330169.SGD","LU2552382132.HKD","LU2286300806.USD","LU0784385840.USD","LU1988902786.USD","IE00B3QW5Z07.USD","LU1366333091.USD","LU0289941410.SGD","SG9999015341.SGD","LU1923622614.USD","IE0004445239.USD","LU2552382058.USD","LU2148611432.USD","LU0061474960.USD","LU1069344957.HKD","LU1861127337.USD","LU2491049909.HKD","LU0690374615.EUR","LU0320765059.SGD","LU0170899867.USD","LU0310800379.SGD","LU0689472784.USD","SG9999015952.SGD","LU1564329032.USD","LU1629891620.HKD","SG9999015358.SGD","IE00BQXX3C00.GBP","SG9999002224.SGD","LU1267930813.SGD","LU1791710400.SGD","LU1674673428.USD","LU0545039389.USD","IE0003U64NQ7.SGD","LU1261432733.SGD","LU1551013425.SGD","LU1670710588.SGD","IE00B64PRP62.GBP","LU0323240290.USD","MSFW","LU2361044949.HKD","LU0426417589.USD","LU1181866309.USD","LU2413666426.HKD","LU2065169927.USD","LU1691799644.USD","LU0545562505.USD","LU1718418525.SGD","LU0171293334.USD","LU2326559502.SGD","LU1564329115.USD","SG9999018865.SGD","IE00BLSP4239.USD","BK4581","LU0912757837.SGD","IE00BN8TJ469.HKD","LU0289961442.SGD","LU1196500208.SGD","IE00B4YYXB79.USD","SG9999017495.SGD","LU1670711123.USD","LU0210528500.USD","LU2242649171.HKD","LU1035773651.USD","LU2168564495.EUR","LU2210150020.SGD","LU0011850046.USD","IE00BMPRXQ63.HKD","LU1989772840.SGD","LU0057025933.USD","SG9999001424.SGD","SG9999014906.USD","BK4579","LU2168564149.EUR","LU2250418816.HKD","LU2097829019.USD","LU0757359368.USD","LU0795875169.SGD","LU0029864427.USD","LU0107464264.USD","LU1803068979.SGD","LU0354030511.USD","IE00BMPRXN33.USD","LU1645745479.HKD","LU0353189680.USD","LU1868836914.USD","LU0234572021.USD","LU1983260115.SGD","BK4112","LU1430594728.SGD","LU0256863902.USD","LU0724617625.USD","LU2023250843.SGD","LU2089284900.SGD","GB00B4QBRK32.GBP","LU1815333072.USD","LU0528227936.USD","LU1235295455.SGD","LU2347655073.USD","BK4543","SG9999002232.USD","LU2168563687.JPY","LU0689626769.HKD","LU2092937148.SGD","LU0096364046.USD","LU1366192091.USD","LU0823434583.USD","LU1732800096.USD","IE00B3SWFQ91.USD","BK4567","LU2023251221.USD","LU2242650005.HKD","LU2023250504.SGD","LU1670710661.SGD","LU1582986359.USD","LU1721428933.USD","LU2360108059.USD","LU2462157665.USD","LU0494093205.USD","LU0162691827.USD","LU1791710582.SGD","IE0005OL40V9.USD","LU0316494557.USD","LU0456855351.SGD","BK4097","LU1582986433.USD","LU0077335932.USD","LU1121112475.USD","LU0080751232.USD","LU1564329628.SGD","LU1066051811.HKD","LU2097344357.USD","LU1506573853.SGD","LU2168564222.USD","LU2275660780.HKD","LU1814569148.SGD","LU2357305700.SGD","LU2087621335.USD","IE00BQXX3F31.USD","LU0820561818.USD","LU1244550221.USD","LU1244550577.SGD","IE00B5TLWC47.USD","LU0187121727.USD","LU0211328371.USD","LU1868837300.USD","LU1202635105.USD","LU1935043536.SGD","SG9999014559.SGD","LU1712237335.SGD","LU1935042215.USD","LU0314104364.USD","LU0823417653.USD","LU0345770993.USD","LU2108987350.USD","LU0868494617.USD","IE0004086264.USD","IE00BN29S564.USD","LU0823421416.USD","SG9999014914.USD","SGXZ51526630.SGD","LU0476273544.USD","LU2404859741.USD","LU0726765562.USD","LU2471134523.USD","LU1732799900.SGD","HK0000914660.USD","SGXZ81514606.USD","LU2237957811.SGD","LU2247934214.USD","LU2471134879.HKD","LU2237443622.USD","LU2506951875.HKD","LU1571399168.USD","BK4592","LU0345774391.USD","LU1670627923.USD","SG9999015945.SGD","LU0960925559.SGD","LU0757359954.USD","SG9999015978.USD","LU1244550494.USD","LU1267930490.SGD","BK4535","LU1720051017.SGD","LU2361044865.SGD","LU0061475181.USD","IE00BDRTCR15.USD","SG9999014039.USD","LU0889565833.HKD","LU1697837992.HKD","LU1116320901.HKD","LU1935043023.USD","MSFU","LU2087625088.SGD","LU1923623000.USD","LU2602419157.SGD","LU2764263203.CNY","LU0061474705.USD","LU1564329461.SGD","LU2491050154.USD","BK4576","LU0198837287.USD","MSFD","IE00BJTD4V19.USD","LU0787776722.HKD","BK4550","LU2452424414.USD","LU1670756490.USD","MSFY","IE0004445015.USD","LU1153585028.USD","IE0034235303.USD","BK4504","IE00B5949003.HKD","LU0672654240.SGD","LU2461242641.AUD","LU1221951129.SGD","LU1989764664.SGD","LU2125909593.SGD","LU0097036916.USD","BK4548","LU2244417387.USD","SG9999004303.SGD","LU1221951046.USD","IE00BSNM7G36.USD","LU2041044095.USD","LU2471134796.USD","LU2506951958.HKD","LU0266013472.USD","LU0390134368.USD","LU0511384066.AUD","LU0557290698.USD","LU1429558221.USD","LU1340139317.AUD","LU1496350502.SGD","LU1551013342.USD","LU0203201768.USD","LU1435385759.SGD","LU0795875086.SGD","GB00B4LPDJ14.GBP","LU2458330243.SGD","LU2506952170.USD","BK4538","LU1989773731.SGD","IE00BFSS8Q28.SGD","LU2095319765.USD","LU0265550359.USD","IE00BN0W2W23.USD","LU0353189763.USD","SG9999014567.USD","LU0154236417.USD","LU1582987597.SGD","IE00BZ1G4Q59.USD","LU0788109477.HKD","LU2463028550.USD","LU0345768740.USD","LU1066053197.SGD","BK4503","LU0109392836.USD","LU0149725797.USD","LU2279689827.SGD","LU0345770308.USD","LU2298321311.HKD","IE00BBT3K403.USD","LU1074936037.SGD","LU0234570918.USD","LU1989764748.USD","LU1674673691.USD","LU2065170008.USD","LU0345768153.USD","LU2133065610.SGD","LU1934455194.USD","LU1043141396.HKD","LU2237443549.SGD","LU2362540622.SGD","LU2487616109.SGD","LU1720051108.HKD","BK4554","LU2236285917.USD","LU0302445910.USD","LU1316542783.SGD","SG9999014575.USD","LU0784383803.USD","LU0069063385.USD","IE00B1XK9C88.USD","SG9999018857.SGD","LU1334329650.SGD","LU2106854487.HKD","SG9999014013.SGD","SG9999014898.SGD","IE000KEQY171.SGD","LU2237443382.USD","LU0861579265.USD","LU1188199696.SGD","BK4516","IE000ITXATA3.USD","LU2063271972.USD","LU0342679015.USD","LU0158827781.USD","LU0661504455.SGD","LU1935042488.USD","LU2168564065.EUR","LU0106261372.USD","LU2404859667.USD","LU1037948541.HKD","LU2756315318.SGD","LU2237438978.USD","LU2237443895.HKD","SG9999014021.USD","LU0965508806.USD","IE000YTNTUN2.SGD","LU0950375773.USD","IE0001KFT4U8.USD","LU0210533765.USD","LU1868837136.USD","LU0738911758.USD","LU1032466523.USD","LU0965509010.AUD","LU0158827948.USD","LU2381873111.SGD","LU0006306889.USD","LU1839511570.USD","IE00BWXC8680.SGD","BK4533","LU0784385170.HKD","IE0004091025.USD","LU1066051498.USD","LU1267930573.SGD","SGXZ99366536.SGD","HK0000914686.HKD","IE00BJJMRY28.SGD","LU2237443465.HKD","LU0225283273.USD","LU0784384876.USD","LU2237957902.USD","LU0128525929.USD","SG9999000418.SGD","LU0553294199.USD","SG9999015986.USD","LU0949170772.SGD","LU0082616367.USD","LU2265009873.SGD","LU2764262908.HKD","LU1235294995.USD","LU2237443978.SGD","LU0708994859.HKD","LU0215105999.USD","LU1069347547.HKD","MSFO","IE00BYXW3230.USD","LU0127658192.USD","LU2764263039.SGD","IE00B775H168.HKD","IE00B19Z8W00.USD","LU0072462426.USD","LU0823421333.USD","LU0871640123.AUD","LU1059921491.USD","LU1623119135.USD","LU0081259029.USD","LU0417517546.SGD","LU0079474960.USD","LU0056508442.USD","LU0444973449.USD","BK4527","LU0354030438.USD","LU2360032135.SGD","LU0792757196.USD","LU2505996681.GBP","LU0472753341.HKD","LU1119994496.HKD","LU2264538146.SGD","LU2420271590.USD","LU2746668974.SGD","LU1280957306.USD","LU2491050071.SGD","LU2125909247.SGD","IE00BYQQ9H92.USD","LU2746668461.USD","LU0211327993.USD","LU1917777945.USD","MSFL","LU0444971666.USD","LU2360106780.USD","LU1868836757.USD","LU1127390331.HKD","IE0034235295.USD","LU2054465674.USD","LU2720916845.USD","LU0894485498.HKD","LU1037948897.HKD","LU1868836591.USD","LU0683600562.USD","SG9999014542.SGD","LU2413666699.HKD","LU1267930730.SGD","LU0238689110.USD","LU0053666078.USD","BK4139","LU2505996509.AUD","LU0823417737.USD","LU0310799852.SGD","LU1585245621.USD","LU2065171402.SGD","LU0957791311.USD","IE00BQXX3D17.EUR","LU0267386448.USD","LU1232071149.USD","LU1914381329.SGD","LU2750360641.GBP","LU0820562030.AUD","IE00BFSS7M15.SGD","LU0289960550.SGD","LU0690374961.EUR","LU0175139822.USD","IE00B1BXHZ80.USD","LU0347712357.USD","LU2097344431.USD","IE00BJTD4N35.SGD","LU1951200564.SGD","LU1323610961.USD","SGXZ23171101.USD","IE00BK4W5M84.HKD","LU1400636657.SGD","LU1815336760.USD","LU2271345857.HKD","LU1934455277.USD","LU1670628061.USD","LU1032955483.USD","IE00B3S45H60.SGD","LU0312595415.SGD","LU1145028129.USD","LU1804176565.USD","LU1084165304.USD","LU0943347566.SGD","LU0820561909.HKD","LU2125154935.USD","LU2211815571.USD","LU1301847155.USD","LU1064131342.USD","LU2543165471.USD","LU2417539215.USD","SGXZ31699556.SGD","BK4587","LU2125154778.USD","LU1974910355.USD","BK4532","LU2092937221.SGD","LU0640476718.USD","LU1934455863.HKD","LU2023250330.USD","BK4598","LU1236620834.HKD","SG9999014005.SGD","IE00BKVL7J92.USD","LU1633808545.USD","LU1236620750.USD","LU0251132253.USD","LU0879622024.SGD","LU2506952097.USD","LU2756315664.SGD","LU0823434740.USD","IE00B775SV38.USD","LU2430703251.USD","GB00BDT5M118.USD","LU0949170426.SGD","LU2403377893.USD","IE00BN0W2T93.GBP","LU0466842654.USD","LU2210149790.SGD","LU2361045086.USD","LU0157215616.USD","LU0348723411.USD","LU1582987324.SGD","LU2860962120.EUR","LU2592432038.USD","LU0314106906.USD","IE00BMPRXR70.SGD","IE0009356076.USD","LU2552382215.SGD","LU2191332357.HKD","LU1046421795.USD","LU0095938881.EUR","MSFX","LU0070217475.USD","IE00BGHQF748.EUR","IE00BHPRN162.USD","IE00BK4W5L77.USD","LU1043141123.HKD","BK4588","LU0276348264.USD","LU0889566641.SGD","LU2362541513.USD","LU0345769631.USD","LU0965509101.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619127891","title":"Tevogen Bio Holdings - Lead Investor Confirmed Intention to Maintain Current Shareholdings","url":"https://stock-news.laohu8.com/highlight/detail?id=2619127891","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619127891?lang=en_us&edition=fundamental","pubTime":"2026-03-14 02:45","pubTimestamp":1773427536,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260313:nFWN4011C1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["TVGN","TVGNW","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619112781","title":"Tevogen Bio Holdings Inc - Board Continues to Evaluate Potential One-Time Special Cash Dividend","url":"https://stock-news.laohu8.com/highlight/detail?id=2619112781","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619112781?lang=en_us&edition=fundamental","pubTime":"2026-03-14 02:45","pubTimestamp":1773427536,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260313:nFWN4011C1:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["TVGNW","TVGN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619112787","title":"Tevogen Bio says it will use no more than 1% of authorized shares over the next 12 months","url":"https://stock-news.laohu8.com/highlight/detail?id=2619112787","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619112787?lang=en_us&edition=fundamental","pubTime":"2026-03-14 02:45","pubTimestamp":1773427518,"startTime":"0","endTime":"0","summary":"Tevogen said its lead investor, Manmohan Patel, intends to maintain his current shareholdings. The company said it does not anticipate using more than 1% of its authorized shares, including placements through its ATM, over the next 12 months or until it becomes cash-flow positive. Tevogen said about one-fifth of total shares outstanding are in the tradable float when accounting for holdings by the lead investor, directors and named executive officers. The board is evaluating a potential one-time special cash dividend contingent on future financial milestones. Tevogen said it is evaluating acquisitions that could generate more than USD 50 million in combined annual revenue, and cited independent valuations in 2022 that estimated the company at more than USD 4 billion before it went public.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260313:nNDLmtSPz:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","BK4112","TVGN","BK4139","IE00B3QW5Z07.USD","IE00B64PRP62.GBP","IE00BKPKM429.USD","LU2095319765.USD","SG9999014005.SGD","SG9999014021.USD","SG9999014039.USD","LU2210149790.SGD","IE00BGHQF748.EUR","LU0314104364.USD","NDAQ","LU2210150020.SGD","SG9999014013.SGD","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619114727","title":"BUZZ - US STOCKS ON THE MOVE-Kyivstar Group, Applied Materials, Tevogen Bio","url":"https://stock-news.laohu8.com/highlight/detail?id=2619114727","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619114727?lang=en_us&edition=fundamental","pubTime":"2026-03-14 01:54","pubTimestamp":1773424469,"startTime":"0","endTime":"0","summary":"BUZZ - US STOCKS ON THE MOVE-Kyivstar Group, Applied Materials, Tevogen BioWorkspace search string for individual stock moves: STXBZThe Day Ahead newsletter: https://refini.tv/3LI4BU7The Morning News ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260313:nL6N4010OX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IBG","INMD","PAR","VACH","CMCT","OFRM","ADBG","INDV","SDHC","CRCD","ULTA","LVWR","TVGN","CRCA","VEON","AMPY","CVNA","ICRC","IMM.AU","HBAN","AIFF","CCUP","SVCO","FITB","KLAR","KLC","CVNY","SANA","BIAF","WDCX","CRCO","KYIV","AMAT","ISPC","CVNX","ARES","RJF","PODD","ESQ","DOUG","CRVS","BW"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2619111673","title":"BUZZ-Tevogen rises as AI platform upgrade boosts drug discovery push","url":"https://stock-news.laohu8.com/highlight/detail?id=2619111673","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619111673?lang=en_us&edition=fundamental","pubTime":"2026-03-14 00:43","pubTimestamp":1773420216,"startTime":"0","endTime":"0","summary":"BUZZ-Tevogen rises as AI platform upgrade boosts drug discovery push** Shares of biotech firm Tevogen Bio TVGN.O rise as much as 7.9% to $6.87 in afternoon trading ** Co says its Tevogen.AI platform improved accuracy in predicting drug targets most likely to work in patients, helping cut trial-and-error in drug development** Platform now analyzes more than 655 mln peptide sequences from about 24 mln proteins, drawing on data from 37 mln scientific papers, co says** TVGN adds its PredicTcell model lifted recall to 92% from 87% and precision to 48% from 40% in recent tests** Says it is seeking partnerships with drugmakers to advance select peptide candidates across cancer, virus and brain disease programs** Shares down ~68% in 2025","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260313:nL4N4011F7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","TVGN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619227111","title":"Tevogen reports performance advancements for Tevogen.AI platform","url":"https://stock-news.laohu8.com/highlight/detail?id=2619227111","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619227111?lang=en_us&edition=fundamental","pubTime":"2026-03-14 00:40","pubTimestamp":1773420031,"startTime":"0","endTime":"0","summary":"Tevogen (TVGN) announced performance advancements for its artificial intelligence platform, operated through Tevogen.AI. Over the past year, the co...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/tevogen-reports-performance-advancements-for-tevogen-ai-platform-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/tevogen-reports-performance-advancements-for-tevogen-ai-platform-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["TVGN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619113431","title":"Tevogen reports PredicTcell Beta recall at 92% and precision at 48%","url":"https://stock-news.laohu8.com/highlight/detail?id=2619113431","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619113431?lang=en_us&edition=fundamental","pubTime":"2026-03-14 00:30","pubTimestamp":1773419416,"startTime":"0","endTime":"0","summary":"Tevogen said beta testing of its PredicTcell model showed recall rising to 92% from 87%, a 5 percentage point increase. Precision increased to 48% from 40%, an 8 percentage point gain. Tevogen said the current version is trained on 1.8 million data points. The company said it has built a proprietary database of more than 655 million peptide sequences and analyzes 37 million scientific publications. Tevogen said Tevogen.AI operates three production AI agents that continuously evaluate 14 active peptide candidates.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260313:nNDL3yBK6K:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BKPKM429.USD","BK4112","LU2210150020.SGD","IE00B3QW5Z07.USD","LU2210149790.SGD","SG9999014005.SGD","SG9999014039.USD","SG9999014013.SGD","TVGN","IE00BGHQF748.EUR","LU0314104364.USD","NDAQ","SG9999014021.USD","BK4139","IE00B64PRP62.GBP","LU2095319765.USD","BK4588","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619113151","title":"Tevogen.AI Reports Advancements in Predictcell™ Beta, Demonstrates Improved Precision Metrics and Expands Proprietary AI Infrastructure","url":"https://stock-news.laohu8.com/highlight/detail?id=2619113151","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619113151?lang=en_us&edition=fundamental","pubTime":"2026-03-14 00:30","pubTimestamp":1773419400,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260313:nTUA6BCVCG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","TVGN","TVGNW"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618978368","title":"Tevogen Bio Holdings Inc - Evaluating Acquisition of Sciometrix and Clinicus Platform for Long Covid Monitoring","url":"https://stock-news.laohu8.com/highlight/detail?id=2618978368","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618978368?lang=en_us&edition=fundamental","pubTime":"2026-03-12 03:15","pubTimestamp":1773256542,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260311:nFWN3ZZ11G:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","TVGNW","TVGN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618978365","title":"Tevogen accelerates TVGN 489 Long COVID program as HLA coverage reaches 65% of U.S. population","url":"https://stock-news.laohu8.com/highlight/detail?id=2618978365","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618978365?lang=en_us&edition=fundamental","pubTime":"2026-03-12 03:15","pubTimestamp":1773256525,"startTime":"0","endTime":"0","summary":"Tevogen said it is accelerating its Biotech and Digital Health verticals to move investigational TVGN 489 into its next clinical phase. Tevogen cited proof-of-concept data showing 100% of treated high-risk patients did not develop Long COVID. The company said identifying five additional HLA targets expanded potential eligibility for TVGN 489 to about 65% of the U.S. population. Tevogen also said it is evaluating the acquisition of Sciometrix and its Clinicus platform for real-world monitoring and data collection in future trials.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260311:nNDL2CYkwn:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NDAQ","IE00BKPKM429.USD","SG9999014013.SGD","LU2095319765.USD","SG9999014021.USD","LU0314104364.USD","LU2210150020.SGD","BK4112","SG9999014039.USD","BK4585","BK4588","IE00BGHQF748.EUR","IE00B64PRP62.GBP","LU2210149790.SGD","TVGN","BK4139","SG9999014005.SGD","IE00B3QW5Z07.USD"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://semperparatusspac.com","stockEarnings":[{"period":"1week","weight":0.4465},{"period":"1month","weight":0.6571},{"period":"3month","weight":-0.482},{"period":"6month","weight":-0.728},{"period":"1year","weight":-0.8144},{"period":"ytd","weight":-0.4775}],"compareEarnings":[{"period":"1week","weight":0.0139},{"period":"1month","weight":0.0856},{"period":"3month","weight":0.0273},{"period":"6month","weight":0.0481},{"period":"1year","weight":0.3701},{"period":"ytd","weight":0.0325}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Tevogen Bio Holdings Inc. operates as a clinical-stage specialty immunotherapy company that develops off-the-shelf precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders. The company develops TVGN 489, which has completed Phase 1 clinical trial for the treatment and prevention of chronic lingering symptoms of the disease (Long COVID), as well as COVID-19 in B cell immune suppressed acute COVID-19 patients without a B cell cancer indication, elderly and infirm acute COVID-19 patients, and acute COVID-19 in patients on T cell suppressing drugs, including solid organ transplant patients. It is also developing TVGN 601 for treating multiple sclerosis; TVGN 930 for the treatment of Epstein-Barr virus associated lymphomas; TVGN 920 for treating cervical cancer; and TVGN 960 for the treatment of mouth and throat cancer. The company was founded in 2020 and is headquartered in Warren, New Jersey.","yearOnYearQuotes":[{"month":1,"riseRate":0.25,"avgChangeRate":-0.040664},{"month":2,"riseRate":0.6,"avgChangeRate":0.049009},{"month":3,"riseRate":0.4,"avgChangeRate":-0.264435},{"month":4,"riseRate":0.6,"avgChangeRate":0.031407},{"month":5,"riseRate":0.25,"avgChangeRate":0.008552},{"month":6,"riseRate":0.25,"avgChangeRate":-0.034979},{"month":7,"riseRate":0.5,"avgChangeRate":-0.078575},{"month":8,"riseRate":0.5,"avgChangeRate":-0.064152},{"month":9,"riseRate":0.5,"avgChangeRate":-0.105281},{"month":10,"riseRate":0.75,"avgChangeRate":1.418967},{"month":11,"riseRate":0.5,"avgChangeRate":-0.189646},{"month":12,"riseRate":0.5,"avgChangeRate":-0.111833}],"exchange":"NASDAQ","name":"Tevogen Bio Holdings","nameEN":"Tevogen Bio Holdings"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Tevogen Bio Holdings(TVGN),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Tevogen Bio Holdings(TVGN) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Tevogen Bio Holdings,TVGN,Tevogen Bio Holdings股票,Tevogen Bio Holdings股票老虎,Tevogen Bio Holdings股票老虎国际,Tevogen Bio Holdings行情,Tevogen Bio Holdings股票行情,Tevogen Bio Holdings股价,Tevogen Bio Holdings股市,Tevogen Bio Holdings股票价格,Tevogen Bio Holdings股票交易,Tevogen Bio Holdings股票购买,Tevogen Bio Holdings股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Tevogen Bio Holdings(TVGN),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Tevogen Bio Holdings(TVGN) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction